Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate
A. Braun, M. Gutmann, T. Mueller, T. Luhmann, and L. Meinel. J Control Release, (2018)Braun, Alexandra C
Gutmann, Marcus
Mueller, Thomas D
Luhmann, Tessa
Meinel, Lorenz
eng
Comparative Study
Research Support, Non-U.S. Gov't
Netherlands
2018/04/11
J Control Release. 2018 Jun 10;279:17-28. doi: 10.1016/j.jconrel.2018.04.009. Epub 2018 Apr 7..
DOI: 10.1016/j.jconrel.2018.04.009
Abstract
PEGylation of protein ligands, the attachment of polyethylene glycol (PEG) polymers to a therapeutic protein, increases therapeutics' half-life but frequently comes at the cost of reduced bioactivity. We are now presenting a bioinspired strategy leading out of this dilemma. To this end, we selected a position within insulin-like growth factor I (IGF-I) for decoration with a PEG(30kDa)-modified protease-sensitive peptide linker (PSL) using a combination of enzymatic and chemical bioorthogonal coupling strategies. The PSL sequence responded to matrix metalloproteinases (MMP) to provide a targeted release in diseased tissue. The IGF-PSL-PEG conjugate had different binding protein affinity, cell proliferation, and endocytosis patterns as compared to the wild type. Exposure of the conjugate to elevated levels of activated MMPs, as present in inflamed tissues, fully reestablished the wild type properties through effective PSL cleavage. In conclusion, this bioinspired approach provided a blueprint for PEGylated therapeutics combining the pharmacokinetic advantages of PEGylation, while locally restoring the full suite of biological potential of therapeutics.
Braun, Alexandra C
Gutmann, Marcus
Mueller, Thomas D
Luhmann, Tessa
Meinel, Lorenz
eng
Comparative Study
Research Support, Non-U.S. Gov't
Netherlands
2018/04/11
J Control Release. 2018 Jun 10;279:17-28. doi: 10.1016/j.jconrel.2018.04.009. Epub 2018 Apr 7.
%0 Journal Article
%1 braun2018bioresponsive
%A Braun, A. C.
%A Gutmann, M.
%A Mueller, T. D.
%A Luhmann, T.
%A Meinel, L.
%D 2018
%J J Control Release
%K Animals myOwn uni_network
%P 17-28
%R 10.1016/j.jconrel.2018.04.009
%T Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate
%U https://www.ncbi.nlm.nih.gov/pubmed/29634992
%V 279
%X PEGylation of protein ligands, the attachment of polyethylene glycol (PEG) polymers to a therapeutic protein, increases therapeutics' half-life but frequently comes at the cost of reduced bioactivity. We are now presenting a bioinspired strategy leading out of this dilemma. To this end, we selected a position within insulin-like growth factor I (IGF-I) for decoration with a PEG(30kDa)-modified protease-sensitive peptide linker (PSL) using a combination of enzymatic and chemical bioorthogonal coupling strategies. The PSL sequence responded to matrix metalloproteinases (MMP) to provide a targeted release in diseased tissue. The IGF-PSL-PEG conjugate had different binding protein affinity, cell proliferation, and endocytosis patterns as compared to the wild type. Exposure of the conjugate to elevated levels of activated MMPs, as present in inflamed tissues, fully reestablished the wild type properties through effective PSL cleavage. In conclusion, this bioinspired approach provided a blueprint for PEGylated therapeutics combining the pharmacokinetic advantages of PEGylation, while locally restoring the full suite of biological potential of therapeutics.
@article{braun2018bioresponsive,
abstract = {PEGylation of protein ligands, the attachment of polyethylene glycol (PEG) polymers to a therapeutic protein, increases therapeutics' half-life but frequently comes at the cost of reduced bioactivity. We are now presenting a bioinspired strategy leading out of this dilemma. To this end, we selected a position within insulin-like growth factor I (IGF-I) for decoration with a PEG(30kDa)-modified protease-sensitive peptide linker (PSL) using a combination of enzymatic and chemical bioorthogonal coupling strategies. The PSL sequence responded to matrix metalloproteinases (MMP) to provide a targeted release in diseased tissue. The IGF-PSL-PEG conjugate had different binding protein affinity, cell proliferation, and endocytosis patterns as compared to the wild type. Exposure of the conjugate to elevated levels of activated MMPs, as present in inflamed tissues, fully reestablished the wild type properties through effective PSL cleavage. In conclusion, this bioinspired approach provided a blueprint for PEGylated therapeutics combining the pharmacokinetic advantages of PEGylation, while locally restoring the full suite of biological potential of therapeutics.},
added-at = {2024-02-15T15:08:22.000+0100},
author = {Braun, A. C. and Gutmann, M. and Mueller, T. D. and Luhmann, T. and Meinel, L.},
biburl = {https://www.bibsonomy.org/bibtex/27d98ec791fd0d322c2770fb36f82430b/jvsi_all},
doi = {10.1016/j.jconrel.2018.04.009},
interhash = {42f1360c803cbda296bef26c61b67aeb},
intrahash = {7d98ec791fd0d322c2770fb36f82430b},
issn = {1873-4995 (Electronic)
0168-3659 (Linking)},
journal = {J Control Release},
keywords = {Animals myOwn uni_network},
note = {Braun, Alexandra C
Gutmann, Marcus
Mueller, Thomas D
Luhmann, Tessa
Meinel, Lorenz
eng
Comparative Study
Research Support, Non-U.S. Gov't
Netherlands
2018/04/11
J Control Release. 2018 Jun 10;279:17-28. doi: 10.1016/j.jconrel.2018.04.009. Epub 2018 Apr 7.},
pages = {17-28},
timestamp = {2024-02-15T15:11:55.000+0100},
title = {Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate},
type = {Journal Article},
url = {https://www.ncbi.nlm.nih.gov/pubmed/29634992},
volume = 279,
year = 2018
}